Categories: News

OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MIAMI, July 20, 2021 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, July 29, 2021. OPKO’s senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on July 29th beginning at 4:30 p.m. Eastern time.

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using the link here. Upon registering, participants will receive dial-in numbers, an event passcode and a unique registrant ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the start of the call. Alternatively, please dial (888) 869-1189 or (706) 643-5902 and use conference ID 7028169

To access the live call via webcast, please click on the link OPKO 2Q21 Results Conference Call. Individual investors and investment community professionals who do not plan to ask a question during the call’s Q&A session are encouraged to listen to the call via the webcast.

For those unable to listen to the live conference call, a replay can be accessed for a period of time on OPKO’s website at OPKO 2Q21 Results Conference Call. A telephone replay will be available beginning approximately two hours after the close of the conference call. To access the replay, please dial (855) 859-2056 or (404) 537-3406, and use conference ID 7028169.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Contacts:

LHA Investor Relations
Yvonne Briggs, 310-691-7100
ybriggs@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Staff

Recent Posts

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

1 hour ago

Clarivate Launches DRG Fusion – A New Life Sciences Analytics Product Powered by Real-World Data

New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes LONDON,…

2 hours ago

Bioz Badges Highlight the Broad Applications of Chondrex Products

PALO ALTO, CALIFORNIA / ACCESSWIRE / January 14, 2025 / Bioz, Inc., a leader in…

2 hours ago

RespondHealth collaborates with Microsoft to advance AI-Powered Real-World Health Intelligence

BETHESDA, Md., Jan. 13, 2025 /PRNewswire/ -- RespondHealth, a real-world evidence (RWE) clinical discovery company, is…

14 hours ago

League Reaches Milestone of 40 Million Contracted Users, 160% Growth Year-Over-Year, Secures $100 Million USD Financing Deal with RBCx

The credit facility will fuel further AI product development, sales capacity, and M&A SAN FRANCISCO,…

14 hours ago

DHS Awards ICF New $40M Digital Engagement Task Order

Collaboration Will Enhance Strategic and Digital Communications and Engagement to Combat Human Trafficking RESTON, Va.,…

14 hours ago